Heart failure prevalence is in excess of 22 million cases worldwide, with 2 million new cases a year. In the US, 670,000 new cases of heart failure are diagnosed each year, affecting 2% of the US population, accounting for 34% of cardiovascular-related deaths, and 1-2% (~$40B) of all health care expenditures.
The cation channel TRPV1 is expressed in the heart, and can be targeted by effective, orally-bioavailable antagonists and agonist-mediated desensitization. Makai Biotechnology research shows that targeting TRPV1 in animal models we can stop heart failure in its tracks and reverse the damage. At Makai we are laser-focused on translating these findings to the clinic and getting new drugs into the hands of physicians and patients.
